Get the Stockscreener App
32.89
0.06%
0.02
Kodiak Sciences Inc stock is traded at $32.89, with a volume of 682.03K.
It is up +0.06% in the last 24 hours and down -21.90% over the past month.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
See More
Previous Close:
$32.87
Open:
$33.1
24h Volume:
682.03K
Relative Volume:
1.01
Market Cap:
$2.07B
Revenue:
-
Net Income/Loss:
$-230.66M
P/E Ratio:
-7.8794
EPS:
-4.1742
Net Cash Flow:
$-148.12M
1W Performance:
-6.99%
1M Performance:
-21.90%
6M Performance:
+34.03%
1Y Performance:
+231.55%
1-Day Range:
$32.31
$34.07
1-Week Range:
$32.31
$35.92
52-Week Range:
$8.91
$47.84
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
32.89 | 2.07B | 0 | -230.66M | -148.12M | -4.1742 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance
Kodiak Sciences (KOD): Three Phase 3 Readouts In SightWill The Data See It Through? - RTTNews
Kodiak Sciences Inc (KOD) Peer Comparison – Compare with Others - valueresearchonline.com
What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak Sciences (KOD) Advances Late-Stage Trials Amid High Valua - GuruFocus
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD - MarketBeat
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell - MarketBeat
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Kodiak Sciences (NASDAQ:KOD) Shares Gap DownTime to Sell? - MarketBeat
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com - Investing.com India
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Kodiak Sciences misses Q2 estimates, shares fall 5% - Investing.com
Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kodiak Sciences Q2 net loss widens on higher R&D costs - TradingView
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026 - TradingView
BRIEF-Kodiak Sciences Q2 Net Income USD -65.643 Million - TradingView
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results - Yahoo Finance
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema - BioPharma APAC
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - TradingView
KOD Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Modest SupportRevenue Recognition Risk - vinanet.vn
Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema - TradingView
Kodiak Sciences (KOD) Begins Enrollment for Phase 3 ALTO Trial T - GuruFocus
Kodiak Sciences enrolls first patients in phase 3 DME trial - Investing.com
Kodiak Sciences starts Phase 3 trial for KSI-50... - Pluang
Kodiak’s Eye Trial Tests Dosing Up to Six Months Apart - Stock Titan
Net margin % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Return on assets % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Kodiak Sciences, Inc. Statistics – HAM:K27 - TradingView
Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed? - Sahm
The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
Kodiak completes enrollment in first KSI-101 trial cohort By Investing.com - Investing.com India
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak completes enrollment in first KSI-101 trial cohort - Investing.com
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 - Yahoo Finance
Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday - MarketBeat
KOD Maintained by JP Morgan -- Price Target Raised to $66.00 - GuruFocus
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):